<DOC>
	<DOCNO>NCT02686164</DOCNO>
	<brief_summary>This multicenter , open-label , non-randomized Phase 1 study participant advance solid tumor , exclude hepatocellular carcinoma ( HCC ) , progressed treatment approve therapy , standard therapy available . The study also include participant radioiodine-refractory differentiated thyroid cancer ( RR-DTC ) . Its primary intent determine effect lenvatinib CYP3A4 activity well assess safety activity lenvatinib participant . The study conduct follow 3 phase : Pretreatment Phase , Treatment Phase , Extension Phase .</brief_summary>
	<brief_title>Phase 1 Study Determine Effect Lenvatinib ( E7080 ) Pharmacokinetics Midazolam Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Age great equal 18 year time inform consent . 2 . Histologically cytologically confirm advanced solid tumor ( exclude HCC ) progress follow standard therapy , standard therapy exists ( include surgery radiation therapy ) participant RRDTC . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Life expectancy great equal 3 month . 5 . Adequately control blood pressure ( BP ) without antihypertensive medication , define BP le equal 150/90 mmHg screen change antihypertensive medication within 1 week prior Cycle 1 Day 1 . 6 . Adequate renal function define calculated creatinine clearance great equal 30 mL/min per Cockcroft Gault formula . 7 . Adequate bone marrow function : 1 . Absolute neutrophil count ( ANC ) great equal 750/mm3 ( great equal 0.75 X 10^9/L ) 2 . Platelets great equal 75,000/mm3 ( great equal 75 X 10^9/L ) 3 . Hemoglobin great equal 9.0 g/dL 8 . Adequate blood coagulation function evidence International Normalized Ratio ( INR ) less equal 1.5 . 9 . Adequate liver function : 1 . Total bilirubin less equal 1.5 X upper limit normal ( ULN ) except unconjugated hyperbilirubinemia Gilbert 's syndrome 2 . Alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 X ULN ( less equal 5 X ULN participant liver metastasis ) . If ALP great 3 X ULN ( absence liver metastasis ) great 5 X ULN ( presence liver metastasis ) AND participant also know bone metastasis , liverspecific ALP must separate total use ass liver function instead total ALP . 10 . Participants Hepatitis B C eligible condition adequate liver function define Inclusion Criterion 9 . 11 . All prior therapy related toxicity must resolve Grade le 2 severity per Common Terminology Criteria Adverse Events ( CTCAE version 4.03 ) , except alopecia infertility . 12 . Left ventricular ejection fraction ( LVEF ) great 50 % echocardiography multiple gated acquisition ( MUGA ) scan . 13 . Females must lactate pregnant screen baseline ( document negative betahuman chorionic gonadotropin [ BhCG ] test minimum sensitivity 25 IU/L equivalent unit BhCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 14 . Participant must voluntarily agree provide write informed consent . 15 . Participant must willing able comply aspect protocol . 1 . Participants diagnosis HCC . 2 . Participants know leptomeningeal metastasis untreated brain metastasis . Participants know brain metastasis eligible complete primary brain therapy ( whole brain radiotherapy , stereotactic radiosurgery , complete surgical resection ) remain clinically stable , asymptomatic , steroid least 28 day . 3 . Participants take medication know potent CYP3A4 inducers/inhibitors substrates narrow therapeutic index St. John 's Wort . 4 . Participants unwilling exclude grapefruit juice grapefruit diet . 5 . Participants receive anticancer treatment within 3 week investigational agent within 30 day first dose study drug recover acute toxicity great Grade 0 1 relate previous anticancer treatment . 6 . Major surgery within 4 week first dose study drug . 7 . Inability take oral medication , malabsorption syndrome uncontrolled gastrointestinal condition ( eg , nausea , diarrhea , vomit ) might impair bioavailability lenvatinib midazolam . 8 . Significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II , uncontrolled arterial hypertension , unstable angina , myocardial infarction , stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment ( include oral anticoagulation ) . 9 . A clinically significant electrocardiogram ( ECG ) abnormality ( ie , correct QT interval [ QTc ] interval great 480 msec electrolyte balance normal ) , history risk factor torsade de pointes , hypokalemia , long QT syndrome , use concomitant medication result prolongation QTc interval . 10 . Active hemoptysis ( bright red blood least 2.5 mL ie , half teaspoon ) within 3 week prior first dose study drug . 11 . Active infection ( infection require treatment ) . 12 . Known hypersensitivity component lenvatinib midazolam . 13 . Prior treatment lenvatinib . 14 . Achlorhydria use antacid , protonpump inhibitor , drug know raise gastric pH within 2 week study drug administration . 15 . Immunocompromised participant , include participant know infected human immunodeficiency virus ( HIV ) . 16 . Any major illness , investigator 's judgment , substantially increase risk associate participant 's participation study . 17 . Females pregnant breastfeed well female childbearing potential : 1. unprotected sexual intercourse within 30 day study entry , 2. agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 28 day study drug discontinuation , 3. currently abstinent , agree use doublebarrier method ( describe ) refrain sexual activity study period 28 day study drug discontinuation , 4. use hormonal contraceptive stable dose hormonal contraceptive product least 4 week dose agree use contraceptive study 28 day study drug discontinuation . All female consider childbearing potential unless postmenopausal ( least 12 month consecutive amenorrheic , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lenvatinib</keyword>
	<keyword>Lenvima</keyword>
	<keyword>E7080</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Midazolam</keyword>
	<keyword>CYP3A4</keyword>
</DOC>